Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

NYSE:AMRX   3:59:56 PM EDT
5.34
+0.02 (+0.47%)
4:00:00 PM EDT: $5.33 -0.01 (-0.09%)
Products, Regulatory, Earnings Announcements

Amneal Announces Positive Topline Results From Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203

Published: 08/25/2021 20:31 GMT
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A (AMRX) - Amneal Announces Positive Topline Results From Pivotal Phase 3 Rise-pd Clinical Trial of Ipx-203 in Patients With Parkinson’s Disease Who Experience Motor Fluctuations.
Amneal Pharmaceuticals Inc - New Drug Application Submission to FDA Planned for Mid-2022.
Amneal Pharmaceuticals Inc - Trial Met Its Primary Endpoint.
Amneal - Secondary Endpoint for Change From Baseline in "off" Time Showed Ipx-203 Resulted in Significantly Less "off" Time Versus Immediate-release Cd/ld.
Revenue is expected to be $543.41 Million
Adjusted EPS is expected to be $0.20

Next Quarter Revenue Guidance is expected to be $562.97 Million
Next Quarter EPS Guidance is expected to be $0.22

More details on our Analysts Page.